21:28 , Jul 19, 2019 |  BC Extra  |  Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation  Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
00:12 , Jul 19, 2019 |  BC Extra  |  Company News

July 18 Company Quick Takes: Mallinckrodt, Silence in RNAi deal; plus Pear, Blueprint and more

Mallinckrodt licenses RNAi candidate from Silence  Mallinckrodt plc (NYSE:MNK) obtained an exclusive, worldwide license to C3-targeted RNAi therapy SLN500 from Silence Therapeutics plc (LSE:SLN), plus options to license up to two additional complement-targeted preclinical candidates....
07:02 , Jul 17, 2019 |  BC Extra  |  Company News

On heels of trial readout, Frequency out-licenses hearing loss therapy to Astellas

Frequency has found a partner in Astellas for its regenerative therapy to treat hearing loss in a deal that will support development of FX-322 as it moves into Phase IIa testing next quarter. Astellas Pharma...
00:02 , Jul 17, 2019 |  BC Extra  |  Company News

Abbisko builds combination strategy with China rights to X4's mavorixafor

Abbisko has licensed Greater China rights to X4’s mavorixafor, which the Shanghai-based company plans to use to develop a pipeline of combination therapies. The deal, for which financial terms are not disclosed, gives Abbisko Therapeutics...
20:22 , Jul 16, 2019 |  BC Extra  |  Financial News

How ophthalmic play Trefoil plans to deploy $28M series A

With $28 million in series A funding, Trefoil plans to submit an IND in early 2020 and complete a Phase IIa proof-of-concept trial of its lead product, TTHX1114, for corneal endothelial dystrophies including Fuchs dystrophy....
23:19 , Jul 15, 2019 |  BC Extra  |  Financial News

July 15 Financial Quick Takes: RA raises $300M for new fund; plus Alphamab and Castle

RA launches $300M VC fund  RA Capital raised $300 million for its first close-ended venture fund, dubbed Nexus, which will invest in private companies backed by the firm's main fund, RA Capital Healthcare Fund L.P....
22:00 , Jul 11, 2019 |  BC Innovations  |  Product Development

How Zymeworks aims to take on Roche’s $10B HER2 franchise

Zymeworks is going head to head with one of the biggest commercial cancer franchises -- Roche’s Herceptin trastuzumab and Perjeta pertuzumab -- as it pursues clinical proof-of-concept for its protein engineering platform. Pivotal readouts in...
21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
23:40 , Jul 2, 2019 |  BC Extra  |  Company News

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

Having gained rights to Incyte’s PD-1 inhibitor, Zai rolled out an immuno-oncology combination strategy it thinks can carve out a space in the crowded Chinese checkpoint inhibitor field. Zai Lab Ltd. (NASDAQ:ZLAB) licensed exclusive rights...
00:18 , Jul 2, 2019 |  BC Extra  |  Company News

Boehringer races to catch up in NASH through Yuhan deal

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy...